Compare HZO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | GLUE |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1998 | 2021 |
| Metric | HZO | GLUE |
|---|---|---|
| Price | $52.45 | $10.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $49.40 | $26.88 |
| AVG Volume (30 Days) | 692.1K | ★ 1.3M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,309,288,000.00 | $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.38 | N/A |
| P/E Ratio | $250.60 | ★ $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $21.42 | $9.68 |
| 52 Week High | $52.65 | $25.77 |
| Indicator | HZO | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 43.86 |
| Support Level | $52.16 | $9.69 |
| Resistance Level | $52.45 | $12.26 |
| Average True Range (ATR) | 0.15 | 0.59 |
| MACD | -0.11 | 0.26 |
| Stochastic Oscillator | 72.22 | 53.64 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).